EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study

Thierry Passeron, Maximilian Reinhardt, Benjamin Ehst, Jonathan Weiss, Jason Sluzevich, Michael Sticherling, Pascal Reygagne, Johannes Wohlrab, Michael Hertl, Nasim Fazel, Elisa Muscianisi, Heng Fan und 2 weitere

British Journal of Dermatology · 2024

DOI: 10.1093/bjd/ljae181 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Thierry Passeron und 13 weiteren Autor:innen. Beteiligte Einrichtung: University Côte d'Azur, CHU Nice, Department of Dermatology, Nice, France. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Lichen Planus, Proof of Concept Study. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with lichen planus (LP) refractory to available therapies often experience a high disease burden, representing a population with a clear unmet need for new treatments.

Objectives

To evaluate the efficacy and safety of secukinumab 300 mg over 32 weeks in adult patients with biopsy-proven cutaneous LP (CLP), mucosal LP (MLP) or lichen planopilaris (LPP) that is inadequately controlled by topical corticosteroids.

Methods

PRELUDE was a randomized double-blind placebo-controlled phase II proof-of-concept study that enrolled patients with CLP, MLP or LPP. Eligible patients were randomized to either secukinumab 300 mg every 4 weeks for 32 weeks (SECQ4W) or placebo for 16 weeks followed by secukinumab 300 mg every 2 weeks (SECQ2W) for 16 weeks. The primary endpoint was achievement of the newly designed Investigator’s Global Assessment (IGA) score ≤ 2 at week 16.

Results

Overall, 111 patients were randomized (n = 37 each) to CLP, MLP and LPP cohorts. As the proof-of-concept criteria were not met for any of the three cohorts, the primary objective was not met. A numerically higher proportion of patients achieved IGA ≤ 2 response at week 16 with SECQ4W vs. placebo in the MLP {37.5% [95% credibility interval (Crl) 20.3–57.2] vs. 23.1% (95% Crl 6.5–49.2)} and LPP cohorts [37.5% (95% Crl 20.2–57.3) vs. 30.8% (95% Crl 10.8–57.6)]. In the LPP cohort, a sustained response for IGA ≤ 2 from week 16 to week 32 was achieved with SECQ4W (week 16, 37.5%; week 32, 45.8%), and a substantial improvement was observed in IGA ≤ 2 response in patients from this cohort who switched from placebo (week 16, 30.8%) to SECQ2W after week 16 (week 32, 63.6%). The safety profile was consistent with the known profile of secukinumab and showed no new or unexpected signals.

Conclusions

PRELUDE is the first randomized controlled basket trial evaluating interleukin (IL)-17A inhibition with secukinumab across three subtypes of LP. Secukinumab was well tolerated and safe, showing different response rates across the three subtypes, with numerical IGA improvements in MLP and LPP, and no response in CLP. The study raises the question of a differential role of IL-17A across LP subtypes. The novel IGA score showed significant correlation with both patient- and physician-reported outcome measurements.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedLichen PlanusProof of Concept StudyHumansDouble-Blind MethodMaleFemaleMiddle AgedAdultTreatment OutcomeAgedDermatologic AgentsDrug Administration Schedule

Substanzen

secukinumabAntibodies, Monoclonal, HumanizedDermatologic Agents

Autor:innen und Institutionen

  • University Côte d'Azur, CHU Nice, Department of Dermatology, Nice, France.
  • University Côte d'Azur, INSERM U1065, C3M, Nice, France.
  • Novartis Pharma, Basel, Switzerland.
  • Oregon Medical Research Center, Portland, OR, USA.
  • Georgia Dermatology Partners, Snellville, GA, USA.
  • Department of Dermatology, Mayo Clinic, Jacksonville, FL, USA.

Förderung

  • Novartis Pharma

Zitieren

APA

Passeron, T., Reinhardt, M., Ehst, B., Weiss, J., Sluzevich, J., Sticherling, M., Reygagne, P., Wohlrab, J., Hertl, M., Fazel, N., Muscianisi, E., Fan, H., Hampele, I., & Compagno, N. (2024). Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae181

Vancouver

Passeron T, Reinhardt M, Ehst B, Weiss J, Sluzevich J, Sticherling M, et al. Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae181

BibTeX
@article{Passeron2024,
  author = {Passeron, Thierry and Reinhardt, Maximilian and Ehst, Benjamin and Weiss, Jonathan and Sluzevich, Jason and Sticherling, Michael and Reygagne, Pascal and Wohlrab, Johannes and Hertl, Michael and Fazel, Nasim and Muscianisi, Elisa and Fan, Heng and Hampele, Isabelle and Compagno, Nicolò},
  title = {Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study},
  journal = {British Journal of Dermatology},
  year = {2024},
  doi = {10.1093/bjd/ljae181}
}
Kostenlos starten →